Since 2005, the Company offers donated $18.5 million to BCRF, with an archive breaking $4.25 million donated this past year alone. The annual contribution expands the Company's longstanding support of advancing lifesaving technology by fully financing seventeen analysis grants this year across the USA and Canada. Supporting the fight breast cancer is indeed near our hearts at ANN INC. Each full 12 months we look forward to rallying our company, our customers and our associates collectively to get BCRF and the company's important function, said Kay Krill, CEO and President of ANN INC.. Today’s announcement marks the 1st clearance to market that the FDA has granted for any monitoring product for CRC since January 14, 1982 when Carcinoembryonic Antigen was accepted. As yet, the CEA check has been the only accepted method cleared in the U.S. DR-70 offers a fresh test that may monitor CRC tumors post-surgery. The DR-70 check is cleared in Canada for the recognition of lung cancers and was recently cleared to import in Korea and Taiwan as a general cancer screen. It also has the CE mark from the European Union accessible in Europe as an over-all cancer screen.

Ada E.D. Teo, B.A., Sumedha Garg, M.Sc., Lalarukh Haris Shaikh, Ph.D., Junhua Zhou, M.Med., Fiona E. Karet Frankl, Ph.D., F.Med.Sci., Tag Gurnell, Ph.D., F.R.C.P., Lisa Happerfield, M.Sc., Alison Marker, F.R.C.Route., Mariann Bienz, Ph.D., F.Med.Sci., Elena A.B.